Worldwide access to treatment for end-stage kidney disease: A systematic review

Thaminda Liyanage, Toshiharu Ninomiya, Vivekanand Jha, Bruce Neal, Halle Marie Patrice, Ikechi Okpechi, Ming Hui Zhao, Jicheng Lv, Amit X. Garg, John Knight, Anthony Rodgers, Martin Gallagher, Sradha Kotwal, Alan Cass, Vlado Perkovic

Research output: Contribution to journalArticle

436 Citations (Scopus)

Abstract

Background End-stage kidney disease is a leading cause of morbidity and mortality worldwide. Prevalence of the disease and worldwide use of renal replacement therapy (RRT) are expected to rise sharply in the next decade. We aimed to quantify estimates of this burden. Methods We systematically searched Medline for observational studies and renal registries, and contacted national experts to obtain RRT prevalence data. We used Poisson regression to estimate the prevalence of RRT for countries without reported data. We estimated the gap between needed and actual RRT, and projected needs to 2030. Findings In 2010, 2·618 million people received RRT worldwide. We estimated the number of patients needing RRT to be between 4·902 million (95% CI 4·438-5·431 million) in our conservative model and 9·701 million (8·544-11·021 million) in our high-estimate model, suggesting that at least 2·284 million people might have died prematurely because RRT could not be accessed. We noted the largest treatment gaps in low-income countries, particularly Asia (1·907 million people needing but not receiving RRT; conservative model) and Africa (432 000 people; conservative model). Worldwide use of RRT is projected to more than double to 5·439 million (3·899-7·640 million) people by 2030, with the most growth in Asia (0·968 million to a projected 2·162 million [1·571-3·014 million]). Interpretation The large number of people receiving RRT and the substantial number without access to it show the need to both develop low-cost treatments and implement effective population-based prevention strategies. Funding Australian National Health and Medical Research Council.

Original languageEnglish
Pages (from-to)1975-1982
Number of pages8
JournalThe Lancet
Volume385
Issue number9981
DOIs
Publication statusPublished - May 16 2015
Externally publishedYes

Fingerprint

Renal Replacement Therapy
Chronic Kidney Failure
Therapeutics
Health Care Costs
Observational Studies
Registries
Biomedical Research
Morbidity
Kidney

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Liyanage, T., Ninomiya, T., Jha, V., Neal, B., Patrice, H. M., Okpechi, I., ... Perkovic, V. (2015). Worldwide access to treatment for end-stage kidney disease: A systematic review. The Lancet, 385(9981), 1975-1982. https://doi.org/10.1016/S0140-6736(14)61601-9

Worldwide access to treatment for end-stage kidney disease : A systematic review. / Liyanage, Thaminda; Ninomiya, Toshiharu; Jha, Vivekanand; Neal, Bruce; Patrice, Halle Marie; Okpechi, Ikechi; Zhao, Ming Hui; Lv, Jicheng; Garg, Amit X.; Knight, John; Rodgers, Anthony; Gallagher, Martin; Kotwal, Sradha; Cass, Alan; Perkovic, Vlado.

In: The Lancet, Vol. 385, No. 9981, 16.05.2015, p. 1975-1982.

Research output: Contribution to journalArticle

Liyanage, T, Ninomiya, T, Jha, V, Neal, B, Patrice, HM, Okpechi, I, Zhao, MH, Lv, J, Garg, AX, Knight, J, Rodgers, A, Gallagher, M, Kotwal, S, Cass, A & Perkovic, V 2015, 'Worldwide access to treatment for end-stage kidney disease: A systematic review', The Lancet, vol. 385, no. 9981, pp. 1975-1982. https://doi.org/10.1016/S0140-6736(14)61601-9
Liyanage, Thaminda ; Ninomiya, Toshiharu ; Jha, Vivekanand ; Neal, Bruce ; Patrice, Halle Marie ; Okpechi, Ikechi ; Zhao, Ming Hui ; Lv, Jicheng ; Garg, Amit X. ; Knight, John ; Rodgers, Anthony ; Gallagher, Martin ; Kotwal, Sradha ; Cass, Alan ; Perkovic, Vlado. / Worldwide access to treatment for end-stage kidney disease : A systematic review. In: The Lancet. 2015 ; Vol. 385, No. 9981. pp. 1975-1982.
@article{0ad1c1f82ae04bb2be12131adaaeb12a,
title = "Worldwide access to treatment for end-stage kidney disease: A systematic review",
abstract = "Background End-stage kidney disease is a leading cause of morbidity and mortality worldwide. Prevalence of the disease and worldwide use of renal replacement therapy (RRT) are expected to rise sharply in the next decade. We aimed to quantify estimates of this burden. Methods We systematically searched Medline for observational studies and renal registries, and contacted national experts to obtain RRT prevalence data. We used Poisson regression to estimate the prevalence of RRT for countries without reported data. We estimated the gap between needed and actual RRT, and projected needs to 2030. Findings In 2010, 2·618 million people received RRT worldwide. We estimated the number of patients needing RRT to be between 4·902 million (95{\%} CI 4·438-5·431 million) in our conservative model and 9·701 million (8·544-11·021 million) in our high-estimate model, suggesting that at least 2·284 million people might have died prematurely because RRT could not be accessed. We noted the largest treatment gaps in low-income countries, particularly Asia (1·907 million people needing but not receiving RRT; conservative model) and Africa (432 000 people; conservative model). Worldwide use of RRT is projected to more than double to 5·439 million (3·899-7·640 million) people by 2030, with the most growth in Asia (0·968 million to a projected 2·162 million [1·571-3·014 million]). Interpretation The large number of people receiving RRT and the substantial number without access to it show the need to both develop low-cost treatments and implement effective population-based prevention strategies. Funding Australian National Health and Medical Research Council.",
author = "Thaminda Liyanage and Toshiharu Ninomiya and Vivekanand Jha and Bruce Neal and Patrice, {Halle Marie} and Ikechi Okpechi and Zhao, {Ming Hui} and Jicheng Lv and Garg, {Amit X.} and John Knight and Anthony Rodgers and Martin Gallagher and Sradha Kotwal and Alan Cass and Vlado Perkovic",
year = "2015",
month = "5",
day = "16",
doi = "10.1016/S0140-6736(14)61601-9",
language = "English",
volume = "385",
pages = "1975--1982",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "9981",

}

TY - JOUR

T1 - Worldwide access to treatment for end-stage kidney disease

T2 - A systematic review

AU - Liyanage, Thaminda

AU - Ninomiya, Toshiharu

AU - Jha, Vivekanand

AU - Neal, Bruce

AU - Patrice, Halle Marie

AU - Okpechi, Ikechi

AU - Zhao, Ming Hui

AU - Lv, Jicheng

AU - Garg, Amit X.

AU - Knight, John

AU - Rodgers, Anthony

AU - Gallagher, Martin

AU - Kotwal, Sradha

AU - Cass, Alan

AU - Perkovic, Vlado

PY - 2015/5/16

Y1 - 2015/5/16

N2 - Background End-stage kidney disease is a leading cause of morbidity and mortality worldwide. Prevalence of the disease and worldwide use of renal replacement therapy (RRT) are expected to rise sharply in the next decade. We aimed to quantify estimates of this burden. Methods We systematically searched Medline for observational studies and renal registries, and contacted national experts to obtain RRT prevalence data. We used Poisson regression to estimate the prevalence of RRT for countries without reported data. We estimated the gap between needed and actual RRT, and projected needs to 2030. Findings In 2010, 2·618 million people received RRT worldwide. We estimated the number of patients needing RRT to be between 4·902 million (95% CI 4·438-5·431 million) in our conservative model and 9·701 million (8·544-11·021 million) in our high-estimate model, suggesting that at least 2·284 million people might have died prematurely because RRT could not be accessed. We noted the largest treatment gaps in low-income countries, particularly Asia (1·907 million people needing but not receiving RRT; conservative model) and Africa (432 000 people; conservative model). Worldwide use of RRT is projected to more than double to 5·439 million (3·899-7·640 million) people by 2030, with the most growth in Asia (0·968 million to a projected 2·162 million [1·571-3·014 million]). Interpretation The large number of people receiving RRT and the substantial number without access to it show the need to both develop low-cost treatments and implement effective population-based prevention strategies. Funding Australian National Health and Medical Research Council.

AB - Background End-stage kidney disease is a leading cause of morbidity and mortality worldwide. Prevalence of the disease and worldwide use of renal replacement therapy (RRT) are expected to rise sharply in the next decade. We aimed to quantify estimates of this burden. Methods We systematically searched Medline for observational studies and renal registries, and contacted national experts to obtain RRT prevalence data. We used Poisson regression to estimate the prevalence of RRT for countries without reported data. We estimated the gap between needed and actual RRT, and projected needs to 2030. Findings In 2010, 2·618 million people received RRT worldwide. We estimated the number of patients needing RRT to be between 4·902 million (95% CI 4·438-5·431 million) in our conservative model and 9·701 million (8·544-11·021 million) in our high-estimate model, suggesting that at least 2·284 million people might have died prematurely because RRT could not be accessed. We noted the largest treatment gaps in low-income countries, particularly Asia (1·907 million people needing but not receiving RRT; conservative model) and Africa (432 000 people; conservative model). Worldwide use of RRT is projected to more than double to 5·439 million (3·899-7·640 million) people by 2030, with the most growth in Asia (0·968 million to a projected 2·162 million [1·571-3·014 million]). Interpretation The large number of people receiving RRT and the substantial number without access to it show the need to both develop low-cost treatments and implement effective population-based prevention strategies. Funding Australian National Health and Medical Research Council.

UR - http://www.scopus.com/inward/record.url?scp=84929606033&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929606033&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(14)61601-9

DO - 10.1016/S0140-6736(14)61601-9

M3 - Article

C2 - 25777665

AN - SCOPUS:84929606033

VL - 385

SP - 1975

EP - 1982

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9981

ER -